A randomized phase 2 DeLLphi-309 analysis presented at the International Association for the Study of Lung Cancer 2026 World Conference on Lung Cancer in Seoul suggested that longer gaps between tarlatamab doses may hold promise in small cell lung cancer. The report focuses on whether extending intervals can preserve efficacy while potentially improving treatment feasibility. The results are positioned as an operational refinement rather than a new mechanism, aligning with broader efforts to reduce burden on patients and infusion centers. In SCLC, where treatment courses can be demanding, dosing cadence can influence adherence and clinic throughput. For competitors and partners developing DLL3- or T-cell–engaging therapies, the readout raises the prospect of route- and schedule-optimization strategies becoming part of late-stage development packages. (Story coverage source: conference coverage.)